News articles about Sophiris Bio (NASDAQ:SPHS) have trended somewhat positive on Friday, Accern Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Sophiris Bio earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.0190956471034 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Sophiris Bio to Present at the Rodman & Renshaw 19th Annual Global Investment Conference (finance.yahoo.com)
- Q3 2017 Earnings Forecast for Sophiris Bio, Inc. Issued By Zacks Investment Research (SPHS) (americanbankingnews.com)
- Tale of the Ticker: Sophiris Bio Inc (SPHS) Moves on Volume – Sheridan Daily (sheridandaily.com)
- Delving Into The Numbers For Sophiris Bio Inc (SPHS) – Evergreen Caller (evergreencaller.com)
- Sophiris Bio, Inc. (SPHS) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com)
Sophiris Bio (SPHS) traded up 2.16% during mid-day trading on Friday, hitting $1.90. The stock had a trading volume of 155,443 shares. Sophiris Bio has a 12 month low of $1.80 and a 12 month high of $6.00. The stock’s market cap is $57.21 million. The stock’s 50-day moving average price is $2.01 and its 200-day moving average price is $2.41.
Sophiris Bio (NASDAQ:SPHS) last announced its quarterly earnings data on Monday, May 15th. The biopharmaceutical company reported ($0.09) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.09). On average, analysts predict that Sophiris Bio will post ($0.31) earnings per share for the current year.
SPHS has been the topic of a number of recent analyst reports. HC Wainwright set a $6.00 price target on shares of Sophiris Bio and gave the stock a “buy” rating in a report on Saturday, June 10th. Maxim Group set a $6.00 price target on shares of Sophiris Bio and gave the stock a “buy” rating in a report on Thursday, June 8th. Rodman & Renshaw reissued a “buy” rating and issued a $6.00 price target on shares of Sophiris Bio in a report on Thursday, June 1st. Finally, ValuEngine downgraded shares of Sophiris Bio from a “hold” rating to a “sell” rating in a report on Tuesday, June 13th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. Sophiris Bio currently has a consensus rating of “Buy” and an average target price of $6.60.
About Sophiris Bio
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Receive News & Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.